# Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer

> **NCT01394211** · PHASE2 · TERMINATED · sponsor: **University of Arizona** · enrollment: 2 (actual)

## Conditions studied

- Estrogen Receptor-positive Breast Cancer
- Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
- Male Breast Cancer
- Recurrent Breast Cancer
- Stage II Breast Cancer
- Stage IIIA Breast Cancer
- Stage IIIB Breast Cancer

## Interventions

- **DRUG:** anastrozole
- **DRUG:** pazopanib hydrochloride
- **PROCEDURE:** therapeutic conventional surgery

## Key facts

- **NCT ID:** NCT01394211
- **Lead sponsor:** University of Arizona
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-07-13
- **Primary completion:** 2012-04-12
- **Final completion:** 2012-04-12
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Slow accrual
- **Last updated:** 2018-07-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01394211

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01394211, "Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01394211. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*